DK3091085T3 - Fremgangsmåde til at designe en terapi mod brystcancermetastase - Google Patents
Fremgangsmåde til at designe en terapi mod brystcancermetastase Download PDFInfo
- Publication number
- DK3091085T3 DK3091085T3 DK15180897.9T DK15180897T DK3091085T3 DK 3091085 T3 DK3091085 T3 DK 3091085T3 DK 15180897 T DK15180897 T DK 15180897T DK 3091085 T3 DK3091085 T3 DK 3091085T3
- Authority
- DK
- Denmark
- Prior art keywords
- designing
- breast cancer
- cancer metastasis
- metastasis therapy
- therapy
- Prior art date
Links
- 206010006187 Breast cancer Diseases 0.000 title 1
- 208000026310 Breast neoplasm Diseases 0.000 title 1
- 206010027476 Metastases Diseases 0.000 title 1
- 230000009401 metastasis Effects 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Biomedical Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hematology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES201031478A ES2379918B1 (es) | 2010-10-06 | 2010-10-06 | Método para el diagnóstico, pronóstico y tratamiento de la metástasis de cáncer de mama. |
| ES201131073 | 2011-06-27 | ||
| EP11791605.6A EP2626431B1 (en) | 2010-10-06 | 2011-10-05 | Method for the diagnosis, prognosis and treatment of breast cancer metastasis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3091085T3 true DK3091085T3 (da) | 2019-05-06 |
Family
ID=45099129
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15180897.9T DK3091085T3 (da) | 2010-10-06 | 2011-10-05 | Fremgangsmåde til at designe en terapi mod brystcancermetastase |
| DK11791605.6T DK2626431T3 (en) | 2010-10-06 | 2011-10-05 | A process for the diagnosis, prognosis and treatment of breast cancer metastasis |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11791605.6T DK2626431T3 (en) | 2010-10-06 | 2011-10-05 | A process for the diagnosis, prognosis and treatment of breast cancer metastasis |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US10047398B2 (enExample) |
| EP (3) | EP3517630B1 (enExample) |
| JP (5) | JP6159254B2 (enExample) |
| KR (2) | KR101944555B1 (enExample) |
| CN (2) | CN108192972B (enExample) |
| AR (1) | AR083357A1 (enExample) |
| AU (4) | AU2011311452B2 (enExample) |
| BR (1) | BR112013008505B1 (enExample) |
| CA (1) | CA2813674C (enExample) |
| DK (2) | DK3091085T3 (enExample) |
| ES (3) | ES2562274T3 (enExample) |
| MX (2) | MX382266B (enExample) |
| WO (1) | WO2012045905A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3517630B1 (en) | 2010-10-06 | 2022-01-19 | Institució Catalana de Recerca i Estudis Avançats | Method for the diagnosis, prognosis and treatment of breast cancer metastasis |
| EP2650682A1 (en) * | 2012-04-09 | 2013-10-16 | Fundació Privada Institut de Recerca Biomèdica | Method for the prognosis and treatment of cancer metastasis |
| EP3467124A1 (en) * | 2012-06-06 | 2019-04-10 | Fundació Institut de Recerca Biomèdica IRB (Barcelona) | Method for the diagnosis, prognosis and treatment of lung cancer metastasis |
| ES2744244T3 (es) * | 2012-10-12 | 2020-02-24 | Inbiomotion Sl | Método para el diagnóstico, pronóstico y tratamiento de metástasis de cáncer de próstata usando c-MAF |
| US10119171B2 (en) | 2012-10-12 | 2018-11-06 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
| EP3272880B1 (en) * | 2013-03-15 | 2020-11-25 | Fundació Institut de Recerca Biomèdica (IRB Barcelona) | Method for the diagnosis, prognosis and treatment of metastatic cancer |
| WO2014184679A2 (en) * | 2013-03-15 | 2014-11-20 | Inbiomotion S.L. | Method for the prognosis and treatment of renal cell carcinoma metastasis |
| WO2014140933A2 (en) * | 2013-03-15 | 2014-09-18 | Fundacio Privada Institut De Recerca Biomedica | Method for the prognosis and treatment of cancer metastasis |
| AU2014333513B2 (en) * | 2013-10-09 | 2020-11-26 | Fundacio Institut De Recerca Biomedica (Irb Barcelona) | Method for the prognosis and treatment of metastasizing cancer of the bone originating from breast cancer |
| EP2933639A1 (en) * | 2014-04-16 | 2015-10-21 | Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts | S100p and Hyaluronic acid as biomarkers for metastatic breast cancer |
| CN104398506A (zh) * | 2014-12-09 | 2015-03-11 | 厦门大学 | 雷奈酸锶在制备预防和治疗腺癌药物中的新用途 |
| CN107001480B (zh) | 2014-12-11 | 2021-12-03 | 生物运动有限公司 | 用于人c-maf的结合成员 |
| KR102867720B1 (ko) | 2016-05-25 | 2025-10-01 | 인바이오모션 에스.엘. | c-MAF 상태에 기초한 유방암의 치료 |
| KR101896558B1 (ko) | 2016-11-21 | 2018-09-07 | 주식회사 젠큐릭스 | 유방암 환자의 예후 예측 방법 |
| CN107699619B (zh) * | 2017-11-17 | 2019-02-22 | 柳超 | lncRNA组合物及制备诊断预示Luminal B型乳腺癌骨转移基因诊断试剂盒的用途 |
| KR20200104298A (ko) * | 2017-11-22 | 2020-09-03 | 인바이오모션 에스.엘. | c-MAF 상태에 기반한 유방암의 요법 치료 |
| JP2023079997A (ja) | 2021-11-29 | 2023-06-08 | 東洋インキＳｃホールディングス株式会社 | 活性エネルギー線硬化型インクジェットインキ及び印刷物 |
| CN114574577A (zh) * | 2022-01-04 | 2022-06-03 | 中山大学孙逸仙纪念医院 | Mettl16基因及其用途 |
| CN119614707A (zh) * | 2025-01-13 | 2025-03-14 | 中山大学 | ERα生物标志物在ER+乳腺癌骨转移诊断、治疗和预后中的应用 |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| EP0217822B1 (en) | 1985-02-13 | 1993-05-12 | Scios Nova Inc. | Human metallothionein-ii promoter in mammalian expression system |
| US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
| US5176996A (en) | 1988-12-20 | 1993-01-05 | Baylor College Of Medicine | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
| US5256775A (en) | 1989-06-05 | 1993-10-26 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides |
| US5264564A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences | Oligonucleotide analogs with novel linkages |
| DE4013632A1 (de) | 1990-04-27 | 1991-10-31 | Max Planck Gesellschaft | Liposomen mit positiver ueberschussladung |
| EP0910652B1 (en) | 1996-04-05 | 2014-10-08 | The Salk Institute For Biological Studies | Hormone-mediated methods for modulating expression of exogenous genes in mammalian systems, and products related thereto |
| CA2274987C (en) | 1996-12-23 | 2012-01-24 | Immunex Corporation | Ligand for receptor activator of nf-kappa b, ligand is member of tnf superfamily |
| US6316408B1 (en) | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
| US6274338B1 (en) | 1998-02-24 | 2001-08-14 | President And Fellows Of Harvard College | Human c-Maf compositions and methods of use thereof |
| YU66101A (sh) | 1999-03-15 | 2004-07-15 | Axys Pharmaceuticals Inc. | Nova jedinjenja i kompozicije kao inhibitori proteaze |
| US6287813B1 (en) | 1999-04-23 | 2001-09-11 | Cistronics Cell Technology Gmbh | Antibiotic-based gene regulation system |
| ATE387199T1 (de) | 2000-01-06 | 2008-03-15 | Merck Frosst Canada Ltd | Neue substanzen und verbindungen als protease- inhibitoren |
| US6750015B2 (en) | 2000-06-28 | 2004-06-15 | Kathryn B. Horwitz | Progesterone receptor-regulated gene expression and methods related thereto |
| NZ530765A (en) | 2001-06-26 | 2006-11-30 | Amgen Fremont Inc | Antibodies that bind OPGL and compositions and methods for the treatment of bone diseases |
| GB0121033D0 (en) | 2001-08-30 | 2001-10-24 | Novartis Ag | Organic compounds |
| AR036375A1 (es) | 2001-08-30 | 2004-09-01 | Novartis Ag | Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos |
| EP1449169A2 (en) | 2001-11-13 | 2004-08-25 | Koninklijke Philips Electronics N.V. | Method for calibration and correction of radial lens distortion |
| KR100485271B1 (ko) | 2002-01-16 | 2005-04-27 | 메타볼랩(주) | 전사인자 ｃ－ｍａｆ의 전사 활성 억제제로서의 니발레놀및 그를 포함하는 약제학적 조성물 |
| SE0201980D0 (sv) | 2002-06-24 | 2002-06-24 | Astrazeneca Ab | Novel compounds |
| DE10235624A1 (de) | 2002-08-02 | 2004-02-19 | Aventis Pharma Deutschland Gmbh | Endiandric acid H und ihre Derivate, Verfahren zu ihrer Herstellung und Verwendung derselben |
| WO2004063355A2 (en) * | 2003-01-10 | 2004-07-29 | Protein Design Labs, Inc. | Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer |
| US20050060771A1 (en) | 2003-09-11 | 2005-03-17 | Farmer Andrew Alan | siRNA encoding constructs and methods for using the same |
| TW200512298A (en) | 2003-09-24 | 2005-04-01 | Oncotherapy Science Inc | Method of diagnosing breast cancer |
| WO2005046731A1 (en) | 2003-10-17 | 2005-05-26 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Interference with c-maf function in multiple myeloma |
| WO2005060722A2 (en) | 2003-12-18 | 2005-07-07 | President And Fellows Of Hardvard College | Modulation of immune system function by modulation of polypeptide arginine methyltransferases |
| TW200526224A (en) | 2003-12-22 | 2005-08-16 | Alcon Inc | Short form c-Maf transcription factor antagonists for treatment of glaucoma |
| CA2558808A1 (en) | 2004-03-05 | 2005-09-22 | Rosetta Inpharmatics Llc | Classification of breast cancer patients using a combination of clinical criteria and informative genesets |
| US20080131940A1 (en) | 2004-06-25 | 2008-06-05 | Robert Chiu | Target Cell-Specific Short Interfering Rna and Methods of Use Thereof |
| WO2006135436A2 (en) | 2004-10-22 | 2006-12-21 | University Of Florida Research Foundation, Inc. | Inhibition of gene expression and therapeutic uses thereof |
| JP5457673B2 (ja) | 2005-09-20 | 2014-04-02 | ベリデックス・リミテッド・ライアビリティ・カンパニー | ユニーク配列のｄｎａプローブを作製するための方法および組成物、ｄｎａプローブの標識、ならびにこれらプローブの使用 |
| US9134237B2 (en) | 2005-09-20 | 2015-09-15 | Janssen Diagnotics, LLC | High sensitivity multiparameter method for rare event analysis in a biological sample |
| WO2007038397A2 (en) | 2005-09-26 | 2007-04-05 | Novartis Ag | Molecular markers associated with bone metastasis |
| EP1969000A2 (en) | 2005-12-06 | 2008-09-17 | Centre National de la Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
| WO2008098351A1 (en) | 2007-02-14 | 2008-08-21 | University Health Network | Treatment of d-cyclin mediated proliferative diseases and hemotological malignancies |
| EP1961825A1 (en) | 2007-02-26 | 2008-08-27 | INSERM (Institut National de la Santé et de la Recherche Medicale) | Method for predicting the occurrence of metastasis in breast cancer patients |
| CN101796072B (zh) | 2007-05-24 | 2014-09-24 | 埃博灵克斯股份有限公司 | 用于治疗骨疾病和病症的针对rank-l的氨基酸序列以及包括其的多肽 |
| CA2688049A1 (en) | 2007-05-31 | 2008-12-04 | Dako Denmark A/S | Methods for utilizing esr copy number changes in breast cancer treatments and prognoses |
| NZ562237A (en) | 2007-10-05 | 2011-02-25 | Pacific Edge Biotechnology Ltd | Proliferation signature and prognosis for gastrointestinal cancer |
| AU2008314459A1 (en) | 2007-10-18 | 2009-04-23 | University Health Network | Clioquinol for the treatment of hematological malignancies |
| WO2009114534A1 (en) | 2008-03-14 | 2009-09-17 | The Regents Of The University Of California | Multi-gene classifiers and prognostic indicators for cancers |
| EP2296654A4 (en) | 2008-06-06 | 2012-04-18 | Univ Health Network | 8-HYDROXYCHINOLINE DERIVATIVES FOR THE TREATMENT OF CRUISING HEMATOLOGICAL DISEASES |
| ES2338843B1 (es) | 2008-07-02 | 2011-01-24 | Centro De Investigaciones Energeticas, Medioambientales Y Tecnologicas | Huella genomica de cancer de mama. |
| WO2010000796A1 (en) | 2008-07-02 | 2010-01-07 | Assistance Publique - Hôpitaux De Paris | A method for predicting clinical outcome of patients with non-small cell lung carcinoma |
| US8642270B2 (en) | 2009-02-09 | 2014-02-04 | Vm Institute Of Research | Prognostic biomarkers to predict overall survival and metastatic disease in patients with triple negative breast cancer |
| WO2010136569A1 (en) | 2009-05-29 | 2010-12-02 | F. Hoffmann-La Roche Ag | Modulators for her2 signaling in her2 expressing patients with gastric cancer |
| EP2486149B1 (en) | 2009-08-06 | 2015-06-17 | John Wayne Cancer Institute | Diagnosis of primary and metastatic basal-like breast cancer and other cancer types |
| EP3517630B1 (en) | 2010-10-06 | 2022-01-19 | Institució Catalana de Recerca i Estudis Avançats | Method for the diagnosis, prognosis and treatment of breast cancer metastasis |
| EP2671076A4 (en) | 2011-02-04 | 2016-11-16 | Bioarray Genetics Inc | METHODS OF USING GENE EXPRESSION SIGNATURES FOR SELECTING A TREATMENT METHOD, PREDICTING PROGNOSIS, SURVIVAL, AND / OR PREDICTING A RESPONSE TO TREATMENT |
| WO2012125828A2 (en) | 2011-03-15 | 2012-09-20 | The University Of North Carolina At Chapell Hill | Methods of treating breast cancer with anthracycline therapy |
| CA2856295A1 (en) | 2011-11-18 | 2013-05-23 | Vanderbilt University | Markers of triple-negative breast cancer and uses thereof |
| EP2650682A1 (en) | 2012-04-09 | 2013-10-16 | Fundació Privada Institut de Recerca Biomèdica | Method for the prognosis and treatment of cancer metastasis |
| EP3467124A1 (en) | 2012-06-06 | 2019-04-10 | Fundació Institut de Recerca Biomèdica IRB (Barcelona) | Method for the diagnosis, prognosis and treatment of lung cancer metastasis |
| ES2744244T3 (es) | 2012-10-12 | 2020-02-24 | Inbiomotion Sl | Método para el diagnóstico, pronóstico y tratamiento de metástasis de cáncer de próstata usando c-MAF |
| US10119171B2 (en) | 2012-10-12 | 2018-11-06 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
| WO2014184679A2 (en) | 2013-03-15 | 2014-11-20 | Inbiomotion S.L. | Method for the prognosis and treatment of renal cell carcinoma metastasis |
| WO2014140933A2 (en) | 2013-03-15 | 2014-09-18 | Fundacio Privada Institut De Recerca Biomedica | Method for the prognosis and treatment of cancer metastasis |
| EP3272880B1 (en) | 2013-03-15 | 2020-11-25 | Fundació Institut de Recerca Biomèdica (IRB Barcelona) | Method for the diagnosis, prognosis and treatment of metastatic cancer |
| AU2014333513B2 (en) | 2013-10-09 | 2020-11-26 | Fundacio Institut De Recerca Biomedica (Irb Barcelona) | Method for the prognosis and treatment of metastasizing cancer of the bone originating from breast cancer |
| CN107001480B (zh) | 2014-12-11 | 2021-12-03 | 生物运动有限公司 | 用于人c-maf的结合成员 |
| KR102867720B1 (ko) | 2016-05-25 | 2025-10-01 | 인바이오모션 에스.엘. | c-MAF 상태에 기초한 유방암의 치료 |
| KR20200104298A (ko) | 2017-11-22 | 2020-09-03 | 인바이오모션 에스.엘. | c-MAF 상태에 기반한 유방암의 요법 치료 |
-
2011
- 2011-10-05 EP EP19159414.2A patent/EP3517630B1/en active Active
- 2011-10-05 AU AU2011311452A patent/AU2011311452B2/en active Active
- 2011-10-05 WO PCT/ES2011/070693 patent/WO2012045905A2/es not_active Ceased
- 2011-10-05 CN CN201810147703.5A patent/CN108192972B/zh active Active
- 2011-10-05 BR BR112013008505-3A patent/BR112013008505B1/pt active IP Right Grant
- 2011-10-05 MX MX2016016496A patent/MX382266B/es unknown
- 2011-10-05 CN CN201180058347.6A patent/CN103339265B/zh active Active
- 2011-10-05 EP EP11791605.6A patent/EP2626431B1/en active Active
- 2011-10-05 US US13/878,114 patent/US10047398B2/en active Active
- 2011-10-05 KR KR1020137011176A patent/KR101944555B1/ko active Active
- 2011-10-05 KR KR1020197001458A patent/KR102240323B1/ko active Active
- 2011-10-05 DK DK15180897.9T patent/DK3091085T3/da active
- 2011-10-05 CA CA2813674A patent/CA2813674C/en active Active
- 2011-10-05 ES ES11791605.6T patent/ES2562274T3/es active Active
- 2011-10-05 MX MX2013003880A patent/MX344315B/es active IP Right Grant
- 2011-10-05 ES ES19159414T patent/ES2911505T3/es active Active
- 2011-10-05 ES ES15180897T patent/ES2721639T3/es active Active
- 2011-10-05 JP JP2013532235A patent/JP6159254B2/ja active Active
- 2011-10-05 DK DK11791605.6T patent/DK2626431T3/en active
- 2011-10-05 EP EP15180897.9A patent/EP3091085B1/en active Active
- 2011-10-11 AR ARP110103721A patent/AR083357A1/es unknown
-
2016
- 2016-11-30 AU AU2016266009A patent/AU2016266009B2/en active Active
-
2017
- 2017-01-26 JP JP2017011967A patent/JP6571698B2/ja active Active
-
2018
- 2018-03-22 JP JP2018054132A patent/JP2018099132A/ja active Pending
- 2018-07-06 US US16/028,530 patent/US11072831B2/en active Active
-
2019
- 2019-03-05 AU AU2019201493A patent/AU2019201493B2/en active Active
- 2019-08-08 JP JP2019146185A patent/JP6946385B2/ja active Active
-
2021
- 2021-06-02 AU AU2021203599A patent/AU2021203599B2/en active Active
- 2021-07-26 US US17/385,568 patent/US12312642B2/en active Active
- 2021-09-15 JP JP2021150170A patent/JP2021192636A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3091085T3 (da) | Fremgangsmåde til at designe en terapi mod brystcancermetastase | |
| IL262100A (en) | Method to use gene expression to determine likelihood of clinical outcome of renal cancer | |
| HUE046790T2 (hu) | A rák kezelésének módszerei | |
| IL258612B (en) | An anti-angiogenic drug for the treatment of ovarian cancer | |
| HUE048876T2 (hu) | Rákos megbetegedések kezelése | |
| IL224370B (en) | Combination treatment for prostate carcinoma | |
| HUE040524T2 (hu) | Mellrák kezelése | |
| EP2536854A4 (en) | PERSONALIZED TUMOR BIOMARKERS | |
| PL2552438T3 (pl) | Sposoby leczenia raka wątrobowokomórkowego | |
| PT3354747T (pt) | Determinação não invasiva de metiloma de tumor a partir de plasma | |
| LT2771307T (lt) | Akrilatų gamybos būdas iš epoksidų | |
| HUE047198T2 (hu) | Fitokannabinoidok emlõrák kezelésére | |
| SMT201600370B (it) | Complessi chelati di oligonucleotidi | |
| DK2717941T3 (da) | Behandling af cancer | |
| PL3299356T3 (pl) | Sposób wytwarzania pleuromutylin | |
| IL225689A0 (en) | Cancer treatment/inhibition of metastasis | |
| IL255309A0 (en) | Reprogramming cancer cells | |
| IL228430A0 (en) | Cancer treatment | |
| EP2791759A4 (en) | HOUSING | |
| BR112013011659A2 (pt) | métodos de tratamento do câncer | |
| BR112012002083A2 (pt) | inibição de metaste tumoral | |
| SMT201600263B (it) | Regimi terapeutici | |
| IT1400092B1 (it) | Metodo di crioconservazione di polpa dentale | |
| GB2510539B (en) | Biomarkers of cancer | |
| DK2405514T3 (da) | Fremgangsmåde til sintring |